Merck KGaA (MRK) Aperçu de l'action
Merck KGaA est une entreprise scientifique et technologique établie en Allemagne. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 1/6 |
| Performances passées | 1/6 |
| Santé financière | 6/6 |
| Dividendes | 5/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour MRK à partir de nos contrôles de risques.
MRK Community Fair Values
Create NarrativeSee what 74 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Merck KGaA Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | €132.05 |
| Plus haut sur 52 semaines | €140.25 |
| Plus bas sur 52 semaines | €100.70 |
| Bêta | 0.81 |
| Variation sur 1 mois | 12.53% |
| Variation sur 3 mois | 20.76% |
| Variation sur 1 an | 17.80% |
| Variation sur 3 ans | -14.94% |
| Variation sur 5 ans | -15.89% |
| Évolution depuis l'introduction en bourse | 751.44% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jun 06
MRK: Life Science Tools Recovery And Lower AI Risk Will Support Upside
Merck KGaA's updated analyst price target now centers around €160, up from €135, with analysts pointing to cautious optimism around life science tools, a more balanced risk and return profile, and sector wide reassessments of recovery potential and valuation. Analyst Commentary Recent research points to a mixed but generally firming stance on Merck KGaA.
Mise à jour du récit • May 23
MRK: Healthcare Resilience And Raised 2026 Guidance Will Support Future Upside
Narrative Update on Merck KGaA Analysts now see fair value for Merck KGaA at about €143, up from roughly €141, reflecting recent price target revisions and views that healthcare could appeal to investors given the current macro backdrop, geopolitical risks, and perceived lower exposure to AI disruption risks. Analyst Commentary Recent research snapshots show a mixed stance on Merck KGaA, with some analysts trimming price targets and others taking a more neutral starting point.Recent updates
Mise à jour du récit • Jun 06
MRK: Life Science Tools Recovery And Lower AI Risk Will Support Upside
Merck KGaA's updated analyst price target now centers around €160, up from €135, with analysts pointing to cautious optimism around life science tools, a more balanced risk and return profile, and sector wide reassessments of recovery potential and valuation. Analyst Commentary Recent research points to a mixed but generally firming stance on Merck KGaA.Mise à jour du récit • May 23
MRK: Healthcare Resilience And Raised 2026 Guidance Will Support Future Upside
Narrative Update on Merck KGaA Analysts now see fair value for Merck KGaA at about €143, up from roughly €141, reflecting recent price target revisions and views that healthcare could appeal to investors given the current macro backdrop, geopolitical risks, and perceived lower exposure to AI disruption risks. Analyst Commentary Recent research snapshots show a mixed stance on Merck KGaA, with some analysts trimming price targets and others taking a more neutral starting point.Mise à jour du récit • Apr 30
MRK: Healthcare Resilience And Sustainable Solvents Will Support Future Upside
The updated analyst price target for Merck KGaA moves modestly lower to about €141 from around €143, reflecting recent target cuts from firms citing a cautious macro backdrop and sector specific views, while still recognizing potential interest in healthcare as investors weigh geopolitical risk and AI related disruption. Analyst Commentary Recent research on Merck KGaA has focused on recalibrating expectations, with multiple firms trimming price targets and one major house initiating coverage with a neutral stance.
Mise à jour du récit • Apr 15
MRK: Reset Expectations And 2026 Guidance Will Shape Future Return Balance
Analysts have trimmed the fair value estimate for Merck KGaA from €127.00 to €112.00, reflecting recent reductions in Street price targets and a more cautious stance on profitability, despite slightly higher modeled revenue growth. Analyst Commentary Recent Street research on Merck KGaA has tilted more cautious, with several bearish analysts cutting price targets and reassessing the risk and reward balance.Mise à jour du récit • Apr 01
MRK: Lower AI Disruption Risk And Margin Resilience Will Support Future Upside
Analysts have trimmed the fair value estimate for Merck KGaA from €187.48 to €172.13 as recent price target cuts and more cautious ratings have offset slightly higher revenue growth and profit margin assumptions, along with a lower future P/E multiple. Analyst Commentary Recent research shows a mixed set of opinions on Merck KGaA, but with some clear pockets of optimism that help frame the trimmed fair value estimate.Mise à jour du récit • Mar 18
MRK: Healthcare Resilience And Limited AI Disruption Will Drive Future Upside
Analysts have trimmed the Merck KGaA fair value estimate from €143.88 to €143.20. This reflects recent cuts to Street price targets in light of a tougher macro backdrop, geopolitical risk and more tempered expectations around sector exposure to AI related disruption.Mise à jour du récit • Mar 04
MRK: Margin Resilience And New TGCT Therapy Will Shape Future Upside
Analysts have lifted their price target on Merck KGaA to €130 from €125, citing slightly stronger assumptions for revenue growth, profit margins and future P/E, even as recent rating changes across the sector keep overall views balanced. Analyst Commentary Recent research on Merck KGaA reflects a split view, with some firms turning more cautious while others highlight steady execution and valuation support.Mise à jour du récit • Feb 18
MRK: Margin Gains And HPC Buildout Will Shape Future Upside Potential
Analysts have raised their price target on Merck KGaA to €130 from €125, citing updated expectations for slightly lower revenue growth, a modestly higher discount rate, and a small uplift in projected profit margin and future P/E assumptions. Analyst Commentary Recent research on Merck KGaA presents a mixed picture, but there is a clear cluster of constructive views around valuation, profitability, and execution.Mise à jour du récit • Feb 03
MRK: Mixed Rating Shifts Will Shape Perceived Balance Of Future Return Potential
Narrative Update: Merck KGaA Analysts have inched their average price target for Merck KGaA up by €5 to €130. This reflects updated views on earnings potential and risk after recent research, including a downgrade at Deutsche Bank and a price target adjustment at Barclays.Mise à jour du récit • Jan 20
MRK: Refined Earnings Outlook Points To Balanced Future Return Potential
Analysts have lifted their fair value estimate for Merck KGaA to €127 from €105, citing updated assumptions for revenue growth, profit margins and future P/E multiples that are broadly in line with recent Street target moves, such as the new €130 level from Barclays. Analyst Commentary The recent move to a €130 price target from €125 sits broadly in line with the updated fair value estimate of €127, which suggests that expectations are being fine tuned rather than reset.Mise à jour du récit • Jan 06
MRK: Future Earnings Power And HPC Expansion May Support Upside
Narrative Update on Merck KGaA Analysts have trimmed their price target for Merck KGaA by €20 to €130, citing updated assumptions that reflect a fair value of €184.63, a discount rate of 4.93%, revenue growth of 5.19%, a profit margin of 16.10%, and a future P/E of 23.44x. Analyst Commentary Recent Street research signals that analysts are reassessing Merck KGaA's valuation framework, with the latest work reflecting a price target of €130 compared with a prior level of €150.Mise à jour du récit • Dec 21
MRK: Future Price Cut Signals Slowing Earnings Momentum Ahead
Analysts have trimmed their price target on Merck KGaA to EUR 130 from EUR 150, reflecting slightly lower long term revenue growth and margin expectations, even as they acknowledge the company's ability to sustain a higher future price to earnings multiple. Analyst Commentary Bearish analysts point to a more challenging backdrop for Merck KGaA, with reduced expectations for long term top line expansion and profitability prompting a reassessment of fair value.Mise à jour du récit • Dec 07
MRK: Margin Strength And AI Deal Will Drive Future Upside
Analysts have trimmed their price target on Merck KGaA, cutting it by EUR 20 to EUR 130 as they factor in slightly softer long term revenue growth assumptions, even though profit margin expectations have improved modestly. Analyst Commentary Analysts are recalibrating their views on Merck KGaA, with the reduced price target reflecting a more measured stance on the company’s medium to long term prospects while acknowledging an improved profitability outlook.Mise à jour du récit • Nov 23
MRK: New Leadership Change And AI Partnership Will Drive Shares Higher
Analysts have modestly lowered their price target for Merck KGaA from €150 to €130. They cite a combination of slightly reduced profit margin forecasts and an increased discount rate, even though there is a small uptick in expected revenue growth.Mise à jour du récit • Nov 03
MRK: Future CEO Appointment Will Support Recovery and Restore Confidence
The analyst price target for Merck KGaA has been reduced from EUR 150 to EUR 130, as analysts cite softer growth expectations and recent earnings disappointments. Analyst Commentary Recent street research reflects a cautious tone among analysts regarding Merck KGaA, with a series of price target reductions and rating adjustments.Mise à jour du récit • Oct 20
Global Biotechnology And Digital Automation Will Drive Future Healthcare
Analysts have trimmed their fair value estimate for Merck KGaA from €147.53 to €145.94. This change reflects a series of recent price target reductions and persistent concerns regarding growth prospects and limited near-term catalysts.Mise à jour du récit • Sep 04
Global Biotechnology And Digital Automation Will Drive Future Healthcare
Merck KGaA's consensus price target remains unchanged at €147.53 as analysts adopt a more neutral stance following disappointing Q2 results, lowered guidance, and reduced near-term growth visibility. Analyst Commentary Disappointing Q2 report and weaker-than-expected operational performance.Article d’analyse • Jul 24
We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • Jul 03
Merck KGaA's (ETR:MRK) Share Price Not Quite Adding Up
With a median price-to-earnings (or "P/E") ratio of close to 19x in Germany, you could be forgiven for feeling...
Nouveau récit • Nov 24
AI-Driven Semiconductor Surge Powers Healthcare And Electronics To New Heights
Strong growth in semiconductor solutions and life sciences boosts Merck's Electronics and Process Solutions sectors, positively impacting future revenue and earnings.Rendement pour les actionnaires
| MRK | DE Pharmaceuticals | DE Marché | |
|---|---|---|---|
| 7D | -4.4% | -2.1% | 1.5% |
| 1Y | 17.8% | 23.1% | 3.3% |
Rendement vs Industrie: MRK a sous-performé le secteur German Pharmaceuticals qui a rapporté 23.1 % au cours de l'année écoulée.
Rendement vs marché: MRK a dépassé le marché German qui a rapporté 3.3 % au cours de l'année écoulée.
Volatilité des prix
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Cours de l'action stable: MRK n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché German.
Volatilité au fil du temps: La volatilité hebdomadaire de MRK ( 5% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1668 | 59,077 | Kai Beckmann | www.emdgroup.com |
Merck KGaA est une entreprise de science et de technologie établie en Allemagne. Elle exerce ses activités dans les secteurs des sciences de la vie, des soins de santé et de l'électronique. Le segment Sciences de la vie de la société propose des outils, des produits chimiques et des équipements pour les laboratoires universitaires, la biotechnologie et les fabricants de produits pharmaceutiques, ainsi que pour le secteur industriel.
Merck KGaA Résumé des fondamentaux
| MRK statistiques fondamentales | |
|---|---|
| Capitalisation boursière | €57.41b |
| Bénéfices(TTM) | €2.53b |
| Recettes(TTM) | €20.96b |
22.7x
Ratio P/E2.7x
Ratio P/SLe site MRK est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| MRK compte de résultat (TTM) | |
|---|---|
| Recettes | €20.96b |
| Coût des recettes | €8.61b |
| Marge brute | €12.35b |
| Autres dépenses | €9.82b |
| Les revenus | €2.53b |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Aug 06, 2026
| Résultat par action (EPS) | 5.82 |
| Marge brute | 58.93% |
| Marge bénéficiaire nette | 12.08% |
| Ratio dettes/capitaux propres | 40.4% |
Quelles ont été les performances à long terme de MRK?
Voir les performances historiques et les comparaisonsDividendes
1.7%
Rendement actuel des dividendes38%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/16 10:45 |
| Cours de l'action en fin de journée | 2026/06/16 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Merck KGaA est couverte par 42 analystes. 15 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Odile Rundquist | Baader Helvea Equity Research |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Charles Pitman | Barclays |